Potential for Future Growth Through Internal InnovationJanuary 3, 2023
Pfizer continues to advance its internal scientific pipeline and strengthen its research and development, investing over $7.8 billion of capital in R&D during the first nine months of 2022 alone.
The company’s business executives and scientific leadership updated investors on Pfizer’s progress at the recent Near-Term Launches and High-Value Pipeline Day, discussing a number of the company’s innovative pipeline programs and an exciting wave of new products that are expected to launch over the next 18 months. Many of these investigational treatments and therapies have the potential to address unmet medical needs.
“Pfizer has an unprecedented number of potential launches over the next 18 months. If successful, these launches, of which we believe more than two-thirds will have the potential to be blockbusters, would be the most ever in Pfizer’s history in such a short period of time,” Chief Financial Officer David Denton said. “Furthermore, to help ensure that we can successfully execute against our plan in such a short period of time, you should expect to see us continue to make important investments in Pfizer. Our 2023 plan contemplates increased investments of both resources and fundings in both our R&D operations as well as our commercial organizations.”
Potential Pfizer Vaccine Breakthroughs in the Making*
Pfizer has a rich history in vaccine research and development. Within vaccines, there are several potential launches planned for 2023.
Pfizer’s respiratory syncytial virus (RSV) vaccine candidate has the potential to help prevent RSV-associated lower respiratory tract illness (LRTI). The company’s RSV vaccine candidate is the only vaccine candidate with potential indications in both older adults and maternal immunization. Pfizer recently received priority review from the U.S. Food and Drug Administration (FDA), for its RSV vaccine candidate for older adults.
In addition, Pfizer is seeking a regulatory decision from the FDA in the second half of 2023, for its pentavalent meningococcal vaccine candidate to prevent invasive meningococcal disease (MenABCWY), an uncommon but serious illness. If approved, Pfizer’s vaccine candidate could provide the broadest serogroup protection in a single vaccine helping to protect against MenABCWY.
Pfizer also saw significant progress across its mRNA vaccine pipeline, including the ongoing development of an mRNA vaccine candidate for influenza, currently undergoing a Phase 3 pivotal trial with an expected readout in 2023. Pfizer and BioNTech are also working to co-develop the first-ever mRNA-based vaccine candidate for shingles, a disease that currently infects one in three Americans during their lifetimes and causes significant pain, suffering, and even death.
Potential Therapies for Immuno-Inflammatory Disease and Cancer*
Pfizer is developing several innovative potential therapies for the treatment of immuno-inflammatory diseases. An investigational JAK3/ TEC inhibitor candidate is being evaluated for the treatment of alopecia areata, a disease characterized by patchy hair loss, that the company hopes could reach the market as early as next year. This is in addition to an approved oral treatment using the Janus Kinase 1 (JAK1) inhibitor for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis.
Pfizer’s oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator candidate is also being evaluated for the potential treatment of moderately to severely active ulcerative colitis, a chronic and often debilitating inflammatory bowel disease that affects an estimated 1 million people in the US. If approved, the company anticipates this candidate could redefine the treatment paradigm when it potentially comes to market in 2023.
In oncology, next year Pfizer hopes to receive regulatory approval and launch its bispecific antibody candidate for triple class refractory multiple myeloma, a blood cancer that affects plasma cells made in the bone marrow. The company also hopes to receive regulatory approval and launch a combination of its PARP inhibitor with an androgen receptor inhibitor for the first-line treatment of metastatic castration-sensitive prostate cancer. The investigational treatments saw positive top-line results in their phase two and three trials, respectively.
For more details on Pfizer’s innovative pipeline, please visit: Product Pipeline: Pharmaceutical Pipeline for New Drugs.
*Subject to clinical and regulatory success.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
 As of October 31, 2022.Research and development figure during the first nine months of 2022.
 Shingles (Herpes Zoster). U.S. Centers for Disease Control and Prevention. Accessed April 18. 2022.
 Janus kinase 3 (JAK3)/Tyrosine kinase expressed in hepatocellular carcinoma (TEC).
 Extrapolation to US population today from Clin Gastroenterol Hepatol. 2017 June;15(6): 857–863.